INTERPRETATION

New Market Entry Pathways of Medical Products: Special Medical Zones in China

by Yinpeng Feng
Apr 21, 2021

In China, many patients resort to unconventional means of receiving treatment for their diseases, like going abroad or relying on surrogate shoppers. According to a New York Times article, in 2017, approximately 600,000 Chinese patients travel abroad to receive medical treatment.1 Although China's review and approval process of drugs has been significantly accelerated after years of reform, certain aspects of China's medical industry still prevent some foreign drugs from reaching the market. For instance, the government's regulation on drug's pricing, the Chinese market's complexity due to the diverse population and vast territory, and the uncertainty of competition from similar products all are able to deter small to middle-sized pharmaceutical companies from investing capitals and conducting clinical trials in China.

Yinpeng Feng
ChemLinked Regulatory Analyst
+ FOLLOW
Copyright: unless otherwise stated all contents of this website are ©2021 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact cleditor@chemlinked.com